Lava Therapeutics N.v.

Lava Therapeutics B.v.

Johannes Jelle Van Der Vliet

Tanja Denise De Gruijl

Renée Cornelia Gerarda De Bruin

Hendrik Marinus Willem Verheul

Roeland Lameris

Paul Willem Henri Ida Parren

Robertus Cornelis Roovers

Victoria Iglesias Guimarais

Lisa Anna King

Iris De Weerdt

Arnon Philip Kater

David Lutje Hulsik

Peter Alexander Gerardus Maria Machielsen

Renee Cornelia Gerarda De Bruin

Roland Lameris

The present invention relates to antibodies capable of binding human PSMA and capable of binding a human Vγ9Vδ2 T cell receptor. The invention further relates to pharmaceutical compositions comprising the antibodies of the invention and to uses of the antibodies of the invention for medical treatment.

Antibodies that bind PSMA and gamma-delta T cell receptors

The invention relates to compounds, in particular polypeptides that specifically bind to the non-classical MHC protein CD1d and modulate CD1d-mediated biological functions. The invention in particular relates to such compounds and polypeptides comprising or consisting of at least one single domain antibody, and wherein at least one single domain antibody specifically binds to CD1d. Also provided is for methods and use employing such compounds, polypeptides and/or single-domain antibodies.

Single domain antibodies targeting CD1d

The present invention relates to novel methods for the treatment of hematological malignancies. In particular, the invention relates to the treatment of hematological malignancies using antibodies comprising a first binding moiety that is able to bind human CD1d and a second binding moiety that is able to bind the human Vγ9Vδ2-TCR.

Bispecific antibodies for use in the treatment of hematological malignancies

The invention is in the field of medicine and relates to immunology, and relates in particular to human V&#x3b3;9V&#x3b4;2 T cell receptor binding immunoglobulin molecules. Human V&#x3b3;9V&#x3b4;2 T cell receptor binding immunoglobulin molecules are in particular for use in medical treatment and/or useful in assays with human V&#x3b3;9V&#x3b4;2 T cells, wherein human V&#x3b3;9V&#x3b4;2 T cells may be modulated.

Immunoglobulins binding human V&#x3b3;9V&#x3b4;2 T cell receptors

Immunoglobulins binding human V&#x3b3;9 V&#x3b4;2 T cell receptors

Growing community of inventors

Amsterdam, Netherlands

Johannes Jelle Van Der Vliet